Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 2

Topical tacrolimus as treatment of atopic dermatitis

Authors Furue M

Published 10 November 2009 Volume 2009:2 Pages 161—166


Review by Single anonymous peer review

Peer reviewer comments 3

Masutaka Furue, Satoshi Takeuchi

Department of Dermatology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan

Abstract: Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. The mainstays of treatment for AD are topical tacrolimus and topical steroids. Tacrolimus, a calcineurin inhibitor, not only complements existing treatment options but also overcomes some of the drawbacks of topical steroid therapy when given topically and thus meets the long-term needs of patients in preventing disease progression. Topical tacrolimus has been widely recognized in terms of its short- and long-term efficacies and safety, and it is also accepted as a first-line treatment for inflammation in AD. The recent proactive use of topical tacrolimus may emphasize a long-term benefit of this calcineurin inhibitor for AD treatment. To reduce possible long-term adverse effects, it is important to monitor its topical doses in daily clinics.

Keywords: atopic dermatitis, topical tacrolimus, topical steroids, dose, proactive use, adverse effects

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]